Drug firm Dr Reddy's Laboratories today reported a 66.58 per cent rise in its net profit to Rs 570.89 crore for the quarter ended March 31, 2013 mainly on account of robust sales across all segments.
The company had posted a net profit of Rs 342.70 crore for the corresponding quarter previous fiscal, the company said in a statement. The company's major segments include global generics, pharmaceutical services and active ingredients.
Net income from sales and services of the company rose to Rs 3,339.94 crore for the quarter under consideration from Rs 2,658.45 crore for the same period year ago. In a separate filing to BSE, the company said its Board of Directors have recommended a final dividend of Rs 15 per share of Rs 5 face value, for the financial year 2012-13.
The company had posted a net profit of Rs 342.70 crore for the corresponding quarter previous fiscal, the company said in a statement. The company's major segments include global generics, pharmaceutical services and active ingredients.
Net income from sales and services of the company rose to Rs 3,339.94 crore for the quarter under consideration from Rs 2,658.45 crore for the same period year ago. In a separate filing to BSE, the company said its Board of Directors have recommended a final dividend of Rs 15 per share of Rs 5 face value, for the financial year 2012-13.
No comments:
Post a Comment